S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Sell every Stock except ONE (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$79.30
+5.87 (+7.99%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$73.89
$79.98
50-Day Range
$50.46
$82.40
52-Week Range
$38.86
$102.99
Volume
281,730 shs
Average Volume
156,090 shs
Market Capitalization
$2.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$105.20

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.7% Upside
$105.20 Price Target
Short Interest
Bearish
6.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.14mentions of Krystal Biotech in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.23) to ($4.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

453rd out of 1,135 stocks

Biological Products, Except Diagnostic Industry

63rd out of 180 stocks

KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech Trading Up 8.0 %

Shares of NASDAQ:KRYS opened at $79.30 on Friday. Krystal Biotech has a 1-year low of $38.86 and a 1-year high of $102.99. The firm has a fifty day moving average price of $68.12 and a 200 day moving average price of $64.62.

Krystal Biotech (NASDAQ:KRYS - Get Rating) last announced its earnings results on Monday, August 8th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.11). On average, research analysts forecast that Krystal Biotech will post -5.23 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on KRYS shares. The Goldman Sachs Group cut their price target on shares of Krystal Biotech from $91.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th. Chardan Capital reduced their target price on Krystal Biotech from $137.00 to $130.00 and set a "buy" rating for the company in a report on Tuesday.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

FDA approves Krystal Biotech clinical trial
Krystal Biotech Files To Seek Approval For Skin Disease Candidate
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings
8/08/2022
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$105.20
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$78.00
Forecasted Upside/Downside
+32.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-69,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$21.79 per share

Miscellaneous

Free Float
21,096,000
Market Cap
$2.03 billion
Optionable
Not Optionable
Beta
0.88

Key Executives

  • Mr. Krish S. Krishnan M.B.A. (Age 57)
    M.S., Founder, Chairman, Pres & CEO
    Comp: $1.01M
  • Ms. Suma M. Krishnan (Age 57)
    Founder, COO, Pres of R&D and Director
    Comp: $708.56k
  • Ms. Kathryn A. Romano (Age 41)
    Exec. VP & Chief Accounting Officer
    Comp: $452.43k
  • Dr. Jing L. Marantz M.B.A. (Age 57)
    M.D., Ph.D., Exec. VP & Chief Bus. Officer
    Comp: $46.7k
  • Dr. Andreas C. Orth (Age 52)
    Exec. VP & Chief Commercial Officer
    Comp: $549.17k
  • Ms. Gloria Lin
    Accounting Mang.
  • Ms. Meg Dodge
    VP of Investor Relations & Corp. Communications
  • Mr. David Glynn
    Gen. Counsel, Commercial & Compliance
  • Mr. John Karakkal
    VP of North American Sales & Marketing
  • Ms. Katherine Tuminello
    HR & Office Mang.













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2022?

4 equities research analysts have issued 1 year price targets for Krystal Biotech's stock. Their KRYS share price forecasts range from $78.00 to $130.00. On average, they anticipate the company's stock price to reach $105.20 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2022?

Krystal Biotech's stock was trading at $69.95 at the start of the year. Since then, KRYS stock has increased by 13.4% and is now trading at $79.30.
View the best growth stocks for 2022 here
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings data on Monday, August, 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by $0.11.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (8.21%), Frazier Life Sciences Management L.P. (4.27%), Pictet Asset Management SA (2.91%), Credit Suisse AG (2.74%), First Light Asset Management LLC (2.32%) and JPMorgan Chase & Co. (1.01%). Insiders that own company stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $79.30.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $2.03 billion. The company earns $-69,570,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 119 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.